title: Evolution of hematological parameters in HIV-1-infected patients with and without thalassemia carriages during highly active antiretroviral therapy.
abstract: OBJECTIVE
  To assess the effects of highly active antiretroviral therapy (HAART) on hematological parameters in HIV-1-infected patients with and without thalassemia carriages.
  
  
  METHODS
  Prospective study was conducted in HIV-1-infected Thai patients receiving HAART. Their hematological parameters were measured at baseline and during follow-up of 1 year. beta-thalassemia and hemoglobin-E trait were diagnosed using HPLC. PCR-genotyping techniques were used to investigate alpha-thalassemia-1 Southeast Asian type deletion and beta-thalassemia mutation. The changes of hematological parameters were compared according to thalassemia carriage.
  
  
  RESULTS
  During follow-up, increased levels of CD4 counts, hemoglobin, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) were observed in the groups of patients with and without thalassemia. The changes in mean hemoglobin level, MCV, and MCH in both groups appeared parallel, with consistently lower levels in patients with thalassemia. At Months 6 and 12, mean MCV of patients with thalassemia was shifted from microcytic levels (<80 fL) to normocytic levels (80-100 fL) while their mean MCH was increased to normal levels (27-31 pg).
  
  
  CONCLUSIONS
  Although HAART altered hematological parameters such as MCV and MCH, it did not induce worsening anaemia, especially in patients with thalassemia carriages. However, the increased levels of MCV and MCH crucially affect the thalassemia screening.
authors.affiliation: Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. sakornmi001@yahoo.com
authors.forename: Sakorn
authors.initials: S
authors.lastname: Pornprasert
authors.forename: Pakhaporn
authors.initials: P
authors.lastname: Sonboon
authors.forename: Suchart
authors.initials: S
authors.lastname: Kiatwattanacharoen
authors.forename: Virat
authors.initials: V
authors.lastname: Klinbuayaem
authors.forename: Prattana
authors.initials: P
authors.lastname: Leenasirimakul
authors.forename: Channat
authors.initials: C
authors.lastname: Promping
authors.forename: Prasit
authors.initials: P
authors.lastname: Inta
authors.forename: Siraporn
authors.initials: S
authors.lastname: Ajhan
authors.forename: Pranee
authors.initials: P
authors.lastname: Leechanachai
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D004909:Erythrocyte Indices / Q000187:drug effects; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D015497:HIV-1; D006454:Hemoglobins / Q000187:drug effects; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D013785:Thailand; D013789:Thalassemia / Q000097:blood* / Q000150:complications / Q000175:diagnosis
chemical_list: D006454:Hemoglobins